Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
NCT06291805

Phenotyping and Characterization of wtATTR-CM (TRACE 1)

Led by Steen Hvitfeldt Poulsen · Updated on 2025-08-15

120

Participants Needed

1

Research Sites

92 weeks

Total Duration

On this page

Sponsors

S

Steen Hvitfeldt Poulsen

Lead Sponsor

N

Novo Nordisk A/S

Collaborating Sponsor

AI-Summary

What this Trial Is About

Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.

CONDITIONS

Official Title

Phenotyping and Characterization of wtATTR-CM (TRACE 1)

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients older than 18 years diagnosed with Wild-type Transthyretin Amyloidosis Cardiomyopathy (ATTRwt-CM) confirmed by endomyocardial biopsy or DPD scintigraphy with Perugini grade 2-3 and genetic testing excluding variant amyloidosis
  • Informed oral and written consent for ATTRwt-CM patient group
  • Patients older than 18 years for control group
  • Informed oral and written consent for control group
Not Eligible

You will not qualify if you...

  • Light-chain amyloidosis (AL amyloidosis)
  • Myelomatosis
  • Waldenström macroglobulinemia
  • Known cardiovascular disease including ischemic heart disease, heart failure, atrial fibrillation, presence of a pacemaker, or malignant hypertension (well-controlled hypertension is allowed) for control group
  • Suspicion of cardiac amyloidosis based on clinical history, physical exam, ECG, or echocardiography signs such as myocardial hypertrophy, apical sparing, infiltrative changes, thickened valves or septum, polyneuropathy symptoms, low ECG voltage, AV block, bilateral carpal tunnel syndrome, spinal stenosis surgery, or elevated troponin I or NT-pro-BNP for control group

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Aarhus University Hospital

Aarhus, Arrhus N, Denmark, 8200

Actively Recruiting

Loading map...

Research Team

S

Sie Kronborg Fensman, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here